Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Madrigal Pharmaceuticals

Verona Pharma

CRISPR Therapeutics' innovative gene-editing therapy could be a game changer. Madrigal Pharmaceuticals hopes to soon win U.S. approval for a potential blockbuster NASH drug.

3 Stocks That Could Be Monster Winners in 2024

Deere & Company

DraftKings

Domino's Pizza

FedEx

Intuit

NIKE

It's time for investors to ditch the search for the mythical crystal ball and instead embrace the algorithms when deciphering the best AI stock for your needs. As hyperbolic as it may sound, the future is here, with progress in artificial intelligence occurring at a rapid clip.

AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. NASDAQ: VRTX announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for patients 12 years or older with recurrent vaso-occlusive crises (VOCs). Casgevy was co-developed with CRISPR Therapeutics AG NASDAQ: CRSP.

CRISPR Therapeutics sets sights on gene-editing cures for disease

Intuitive Surgical

Teladoc

If you had to bet on two “big picture” sectors to invest in for the long haul, you can't go wrong with technology or healthcare. Both are omnipresent and, in their own ways, on the cutting edge of global innovation that cement their longevity as investable opportunities.

3 Healthcare Technology Stocks to Improve Lives in 2024

bluebird bio

By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.

3 Money-Saving Tricks for Investing in Biotech Stocks in 2024

Amazon

Etsy

There are some good reasons why you should put your money to work right now instead of waiting. Your moves today could pay off over the long run.

I'm Begging You to Buy Stocks Before January -- Here's Why

The stock market has been responding to the recent approval of CRISPR Therapeutics' first drug. A successful commercial launch for Casgevy could make the biotech stock a top performer in 2024, but that's far from guaranteed.

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?

CRISPR Therapeutics now has an approved gene therapy treatment in Casgevy. The treatment for sick cell disease received regulatory approval earlier this month.

6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy

Pfizer

CRISPR Therapeutics just reached a major milestone: approval of its first product. Pfizer is cheap and could deliver market-beating total returns thanks to its juicy dividend.

Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock

Phuong Khanh Morrow, chief medical officer at gene editing company Crispr Therapeutics (NASDAQ: CRSP ), resigned unexpectedly. The move comes a month after Crispr won Food and Drug Administration (FDA) approval for its first gene therapy.

CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief

Crispr Therapeutics CRSP, +8.84% on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company's chief medical officer, a move that takes hold on Jan. 26. The resignation was “not the result of any disagreement with the company,” Crispr said in a filing.

Crispr Therapeutics chief medical officer is resigning

Recursion Pharmaceuticals

Twist Bioscience Corp

Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.

3 Genomics Stocks to Unlock the Future of Medicine

Johnson & Johnson

You probably won't get rich with just one stock, but you could reach your goal by investing in a portfolio of solid companies over time. Two of these players offer you revenue growth potential, and the third could lift your investment thanks to dividends.

3 Healthcare Stocks That Could Help Make You a Millionaire

Dynavax Technologies

Intra-Cellular Therapies

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

Block

CRISPR Therapeutics is blazing new trails in the promising area of gene editing. Block's two central ecosystems and several other ventures promise a bright future.

2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years

CRISPR Therapeutics and Vertex Pharmaceuticals just launched a gene therapy. For now, it's a pricey medicine, and there aren't many eligible patients.

CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?

The main reason to consider buying CRISPR Therapeutics has little to do with its newly approved gene-editing therapy. Instead, the biotech's promising pipeline is the key factor that should be attractive.

Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip

Arcellx

Revolution Medicines

The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.

Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development

CRISPR Therapeutics won regulatory approval of its first product, Casgevy, for blood disorders. This is also the world's first approval of a treatment based on CRISPR gene editing.

After This Landmark Win, Is CRISPR Therapeutics a Buy?

Axcelis Technologies

Sigma Lithium Corp

Small-cap stocks are often overlooked yet they can provide investors with significant potential for outperformance. That said, not all small-cap stocks are worth considering.

3 Small-Cap Stocks That Could Skyrocket 1000% by 2030

Amgen's pioneering efforts in antibody drug development turned out to be a game changer for early shareholders. CRISPR Therapeutics could follow a similar path, following its historic approval for Casgevy this month.

1 Biotech Stock That Could Be the Next Amgen

Caribou Biosciences

Intellia Therapeutics

Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.

3 Gene-Editing Stocks With the Potential to Mint Millionaires

Vertex Pharmaceuticals

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren't without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine

Crispr Therapeutics AG ( NASDAQ:CRSP) stock is down 7.2% to trade at $59.89 at last check, despite its gene therapy treatment for sickle cell disease in partnership with Vertex (VRTX) last week receiving approval from the U.S. Food and Drug Administration (FDA).

Crispr Therapeutics Stock Sinks Despite FDA Approval

The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.

News for CRISPR Therapeutics Stock (CRSP)